# US Molecular Modeling Market > 美国分子建模市场研究报告按产品（软件、服务）、按应用（药物开发、药物发现）和按最终用户（制药和生物技术公司、研究和学术中心） - 2025年至2035年的增长和行业预测 - **Forecast Period:** 2025 - 2035 - **CAGR:** 16.3% - **2024:** $ 95 Million - **2025:** $ 110.48 Million - **2035:** $ 500 Million - **Key Players:** Schrodinger (US), Accelrys (US), Biovia (US), ChemAxon (HU), Molecular Simulations (US), OpenEye Scientific Software (US), Cresset (GB), Simulations Plus (US), Zinc (US) **Report ID:** MRFR/HC/17902-HCR · **Pages:** 100 · **Author:** Vikita Thakur & Garvit Vyas · **Last Updated:** September 10, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-molecular-modeling-market-19449 --- ## Market Summary ## **US Molecular Modeling Market Overview** As per MRFR analysis, the US Molecular Modeling Market Size was estimated at 69.56 (USD Million) in 2023. The US Molecular Modeling Market Industry is expected to grow from 80.87(USD Million) in 2024 to 412.54 (USD Million) by 2035. The US Molecular Modeling Market CAGR (growth rate) is expected to be around 15.967% during the forecast period (2025 - 2035). ### **Key US Molecular Modeling Market Trends Highlighted** The US Molecular Modeling Market is witnessing several significant trends that are shaping its landscape. One key market driver is the increasing utilization of molecular modeling in drug discovery and development processes. Pharmaceutical companies are leveraging these advanced modeling techniques to enhance the efficiency of their research and expedite the time-to-market for new medications. This trend is being further propelled by the rising demand for personalized medicine, as molecular modeling facilitates the understanding of patient-specific responses to drugs. There are also ample opportunities to be explored in the field of education and training in molecular modeling. As the technology advances, educational institutions are incorporating molecular modeling into their curricula, preparing a skilled workforce ready to tackle challenges in biotechnology and pharmaceuticals. Government initiatives aiming to strengthen the biomedical research sector in the US further complement this trend by investing in technology development and fostering collaborations between academia and industry. Moreover, recent times have seen an increase in cloud-based molecular modeling solutions, which offer flexibility and accessibility to researchers. These solutions lower the barriers for startups and smaller firms, enabling them to compete in the market with established players. Additionally, there is an ongoing trend toward integrating artificial intelligence and machine learning with molecular modeling, which could lead to breakthroughs in predictive analytics and optimization in drug design. Together, these trends reflect a dynamic transformation of the US Molecular Modeling Market, driven by technological advancements and the pressing needs of the healthcare industry. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **US Molecular Modeling Market Drivers** #### **Increasing Demand for Drug Discovery and Development** The US Molecular Modeling Market Industry is experiencing significant growth due to the increasing demand for effective drug discovery and development processes. The National Institutes of Health (NIH) reports that in the past decade alone, there has been a dramatic increase in the number of clinical trials conducted, with over 40,000 trials registered in 2020, compared to approximately 12,000 in 2000. This surge in clinical trials is a direct result of the escalating need for novel therapeutics, particularly in response to emerging health challenges such as the COVID-19 pandemic. Major pharmaceutical companies like Pfizer and Johnson & Johnson are actively investing in molecular modeling tools to streamline their Research and Development (R&D) efforts. By leveraging advanced molecular modeling techniques, these organizations enhance their ability to predict drug interactions, optimize lead compounds, and reduce the time required for bringing new drugs to market. As a result, this escalating demand creates a robust environment for growth within the US Molecular Modeling Market. #### **Technological Advancements in Computational Chemistry** Recent technological advancements in computational chemistry have significantly contributed to the growth of the US Molecular Modeling Market Industry. These advancements include the development of more sophisticated algorithms and software packages that enable researchers to perform highly detailed simulations. According to the American Chemical Society, the number of cited publications in the field of computational chemistry has increased by 30% over the last five years, indicating a strong interest in utilizing these tools by the scientific community. Prominent software platforms such as Schrdinger and ChemAxon have revolutionized the molecular modeling process, allowing scientists to explore complex molecular structures with precision. As a result, the proliferation of these advanced technologies continues to drive investment in molecular modeling, leading to a brighter future for the industry. #### **Growing Focus on Personalized Medicine** The shift towards personalized medicine is a notable driver for the growth of the US Molecular Modeling Market Industry. The Food and Drug Administration (FDA) has recognized the importance of tailoring treatment options to individual patient characteristics, resulting in an increase in approvals for targeted therapies. In recent years, the FDA has granted approval to over 100 New Drug Applications (NDAs) specifically intended for personalized treatment, showcasing an industry trend that prioritizes individualized healthcare. Companies like Amgen and Genentech are leveraging molecular modeling to understand patient-specific disease mechanisms better, allowing them to innovate treatments that are customized for small patient populations. This focus on personalized medicine not only enhances patient outcomes but also generates increased demand for sophisticated molecular modeling solutions, opening new avenues for growth in the US market. ### **US Molecular Modeling Market Segment Insights** #### **Molecular Modeling Market Product Insights** The US Molecular Modeling Market is experiencing significant growth, driven by advancements in biotechnology and computational techniques. The Product segment of this market can be broadly categorized into two important areas: Software and Services. The Software segment has become a crucial cornerstone for researchers, providing essential tools that enable the simulation of molecular interactions, thereby aiding in drug discovery and materials science. Increased demand for precise modeling in Research and Development processes, along with the rise of personalized medicine, highlights the software's instrumental role in enhancing predictive accuracy and efficiency. In parallel, the Services aspect is equally vital, comprising consulting and support services that help end-users maximize their software capabilities. These services facilitate the effective implementation of molecular modeling solutions, ensuring that organizations can extract the full value of their investments. The evolution of cloud-based services is also shaping the market landscape, offering scalable options to laboratories and organizations that need flexible access to computational resources without hefty capital expenditures. Trends observed in this segment indicate that as the complexity of molecular systems increases, so does the necessity for sophisticated software applications and specialized services, which in turn accelerates market growth. The ongoing developments in artificial intelligence and machine learning are expected to further strengthen the capabilities of both software and services, allowing for even deeper insights into molecular behavior. As these elements continue to unfold, it is clear that the US Molecular Modeling Market is poised for robust expansion, with the Product segment playing a pivotal role in advancing scientific discovery and innovation. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review #### **Molecular Modeling Market Application Insights** The US Molecular Modeling Market, particularly within the Application segment, demonstrates significant growth driven by advancements in technology and its integral role in the pharmaceutical landscape. Drug Development is crucial, as it streamlines the discovery process, reducing the time and costs associated with bringing new drugs to market. Molecular modeling methodologies, including simulations and predictive analytics, enable researchers to better understand molecular interactions, thereby enhancing specificity and efficacy in drug design. Similarly, Drug Discovery employs molecular modeling to identify potential drug candidates more efficiently, fostering innovation in therapeutic areas such as oncology and infectious diseases. The integration of artificial intelligence and machine learning within these applications is expected to further accelerate progress, adapting to complex biological systems. As the US aims to remain at the forefront of healthcare advancements, these applications are pivotal in contributing to improved patient outcomes and addressing the ongoing challenges in drug development. The growing emphasis on personalized medicine is evident, as molecular modeling continues to play a vital role in tailoring therapies to individual genetic profiles. This strategic focus on application-driven insights underscores the importance of the US Molecular Modeling Market in enhancing drug efficacy and safety. #### **Molecular Modeling Market End User Insights** The End User segment of the US Molecular Modeling Market is primarily composed of Pharmaceutical and Biotechnology Companies as well as Research and Academic Centers, both of which play a crucial role in driving the advancements in this field. Pharmaceutical and Biotechnology Companies are pivotal to the market as they utilize molecular modeling techniques for drug design and discovery, significantly improving the speed and efficacy of bringing new therapies to the market. These companies often account for a substantial portion of the market, leveraging sophisticated simulation tools to understand molecular interactions. On the other hand, Research and Academic Centers contribute significantly by conducting fundamental research that forms the basis for innovative applications in molecular modeling. They are essential for educating future scientists and developing novel methodologies that enhance the industry’s capabilities. The growth of these sectors is driven by increasing investments in drug discovery, rising healthcare demands, and expanding collaborations between industry and academia. As the field evolves, both Pharmaceutical and Biotechnology Companies and Research and Academic Centers are expected to continuously adapt and innovate, ensuring the US remains a leader in molecular modeling advancements. This dynamic interaction between industry needs and academic research fosters a rich environment for the expansion of the US Molecular Modeling Market and stimulates ongoing innovations. ### **US Molecular Modeling Market Key Players and Competitive Insights** The US Molecular Modeling Market has become increasingly competitive, driven by advancements in computational technologies and the rising demand for drug discovery, materials science, and biological research. As the market continues to grow, various players are strategizing to enhance their product offerings and capture significant market share. This involves leveraging cutting-edge software solutions, improving user experiences, and incorporating machine learning and artificial intelligence into molecular modeling processes. Additionally, partnerships and collaborations are critical in ensuring that companies can provide comprehensive services that meet the evolving needs of researchers and industries alike. The competition is further intensified by ongoing innovations and the need for companies to differentiate their products in a crowded space, leading to a dynamic landscape where market leaders vie for technological supremacy. In the competitive realm of the US Molecular Modeling Market, BIOVIA has established a strong presence with its extensive suite of software solutions aimed at aiding researchers in simulations and molecular design. Known for its user-friendly interfaces and robust functionalities, BIOVIA excels in providing tools that facilitate predictive modeling and enable users to achieve greater insights in their research and development endeavors. The company's strengths lie in its integration capabilities with other software tools and platforms, offering seamless workflows for scientific teams. Additionally, BIOVIA's commitment to constant innovation and user feedback allows it to continually enhance its offerings, thereby solidifying its position as a prominent player in the US market. Hillhouse Capital, while primarily recognized for its investment strategies, has made significant inroads into the US Molecular Modeling Market through strategic investments and partnerships with technology firms. The focus on identifying breakthrough technologies and providing funding has spurred growth in innovative products and services aimed at molecular modeling and simulations. Hillhouse Capital's strengths lie in leveraging its extensive network and industry knowledge to facilitate mergers and acquisitions that enhance the capabilities of the companies within its portfolio. This has led to a more comprehensive suite of solutions tailored to address market demands in drug discovery, biotechnology, and materials science. The strategic vision of Hillhouse Capital in the US Molecular Modeling Market reflects an understanding of the importance of collaboration and technological advancement, positioning it as a key influencer in shaping the future of molecular modeling applications. #### **Key Companies in the US Molecular Modeling Market Include** ### **US Molecular Modeling Market Industry Developments** The US Molecular Modeling Market has been active recently, with companies such as BIOVIA and Dassault Systemes focusing on advancing their software capabilities to better serve the pharmaceutical and biotechnology sectors. In September 2023, Schrodinger announced a significant collaboration with a leading biotech firm to enhance drug discovery processes through advanced molecular simulations. Additionally, Sygnature Discovery and Hillhouse Capital have been reported to collaborate on a new project aimed at utilizing machine learning in molecular modeling, targeting better prediction of drug interactions. In terms of mergers and acquisitions, OpenEye Scientific Software acquired the tech assets of a small startup to bolster their computational capabilities, which was publicly announced in October 2023. The market has seen considerable growth, with recent valuations reaching upward of $1 billion, driven by increased investments in Research and Development from companies like Luminex and ChemAxon that are enhancing their platforms for scientific research. Over the past few years, the emphasis on personalized medicine and advancements in artificial intelligence have shaped market dynamics, prompting key players to seek innovative solutions in molecular modeling. ### **US Molecular Modeling Market Segmentation Insights** #### **Molecular Modeling Market Product Outlook** #### **Molecular Modeling Market Application Outlook** #### **Molecular Modeling Market End User Outlook** ## Market Drivers ### Rising Demand for Drug Discovery 分子建模市场正经历显著的需求激增，这主要是由于对高效药物发现过程的需求不断增加。制药公司越来越多地采用分子建模技术，以简化潜在药物候选者的识别。这一转变主要归因于与传统药物开发相关的成本上升，批准的每种药物成本可能超过26亿美元。通过利用分子建模，公司可以减少药物开发所需的时间和资源，从而可能缩短上市的平均时间。因此，预计分子建模市场在未来五年内将以约12%的年复合增长率增长，反映出行业对创新和效率的承诺。 ### Advancements in Computational Power 分子建模市场受到计算能力进步的显著影响，这使得更复杂的模拟和分析成为可能。高性能计算（HPC）系统的发展使研究人员能够进行以前无法实现的分子动力学模拟。这种计算能力的提升促进了对更大分子系统和更复杂相互作用的探索，从而提高了药物设计和材料科学中预测的准确性。随着计算资源变得更加可获取，分子建模市场可能会扩展，预计年增长率约为10%。这一趋势强调了技术在推动行业创新中的重要性。 ### Increased Investment in Biotechnology 分子建模市场受益于对生物技术领域投资的增加，该领域正成为医疗保健和制药创新的重点。近年来，生物技术公司的风险投资激增，投资额超过200亿美元。这一资金的涌入使公司能够利用分子建模技术开发新疗法并改善现有治疗。随着生物技术的不断发展，预计分子建模市场的需求将相应上升，预计未来几年增长率约为11%。这一趋势突显了财政支持在推动分子建模应用中的关键作用。 ### Growing Focus on Sustainable Practices 分子建模市场正见证对可持续实践的日益关注，特别是在绿色化学和环保药物开发的背景下。随着对环境问题的认识提高，制药公司越来越多地寻求减少生态足迹的方法。分子建模在这一转型中发挥着至关重要的作用，使得设计更高效和更少有害的化学过程成为可能。通过优化分子结构和预测环境影响，公司可以开发符合监管标准的可持续产品。这一向可持续性转变的趋势预计将推动分子建模市场的增长，预计未来几年市场规模可能增加8%。 ### Regulatory Support for Innovative Therapies 分子建模市场受到旨在促进创新疗法发展的监管支持的积极影响。美国的监管机构越来越认识到计算建模在加速药物审批过程中的价值。FDA关于在药物开发中使用建模和模拟的指导方针等举措正在鼓励制药公司采用这些技术。这一监管支持不仅增强了分子建模的可信度，还促进了其在行业标准实践中的整合。因此，预计分子建模市场将经历增长，估计未来几年将增加约9%。 ## Future Outlook 分子建模市场预计将在2025年至2035年期间以16.3%的年均增长率增长，推动因素包括计算技术的进步和对药物发现的需求增加。 到2035年，分子建模市场预计将实现显著增长和创新。 ## Segment Insights ### 按产品：软件（最大）与服务（增长最快） 美国分子建模市场的市场份额分布显示，软件部门占据了显著份额，得益于其在各种研发活动中的强大应用。该部门的特点是制药和生物技术行业对复杂分子模拟和预测分析的软件解决方案的强烈需求。 相比之下，服务部门正在迅速获得关注，成为市场中增长最快的领域。这一趋势主要归因于分子建模技术的日益复杂化，以及有效实施这些先进解决方案所需的专业咨询和支持服务。随着组织寻求增强其建模能力，对专家服务的需求预计将激增。 软件（主导）与服务（新兴） 软件部门代表了美国分子建模市场的主导力量，其特点是提供全面的解决方案，促进各种分子模拟、可视化和数据分析任务。该领域的主要参与者不断创新，以提供满足研究人员和科学家不断变化需求的尖端能力。另一方面，服务部门虽然是新兴的，但随着组织越来越认识到在复杂建模环境中专业知识的价值，正在迅速变得至关重要。服务提供商专注于量身定制的支持和咨询，提升其产品以满足客户的具体需求，从而加速先进分子建模技术的采用。 ### 按应用：药物开发（最大）与药物发现（增长最快） 在美国分子建模市场中，药物开发部门占据了最大的市场份额，得益于对高效和成本效益药物生产过程的日益需求。该部门专注于新分子的创建和优化，简化了从实验室到市场的过程，满足广泛的治疗需求。另一方面，药物发现部门已成为增长最快的领域，因计算技术的进步和对各种疾病领域新型治疗药物的迫切需求而获得关注。 这些部门的增长趋势反映了制药研究中向更综合和技术驱动的方法的持续转变。个性化医学和智能药物的兴起等因素正在显著影响市场格局。此外，人工智能和机器学习在药物研究中的日益整合正在推动药物发现部门的发展，展示出向创新和快速发展的明确趋势，而药物开发在其既定角色中仍然保持强劲。 药物开发（主导）与药物发现（新兴） 药物开发部门以其在将初始药物概念转化为可行市场产品中的关键角色而著称，得益于强大的监管框架和广泛的临床前测试。该部门受益于成熟的基础设施，使公司能够成功应对复杂的监管环境。相反，药物发现部门正在迅速崛起，受到突破性技术和方法的推动，这些技术和方法允许更快地识别和验证药物候选者。该部门越来越多地以学术界和工业界之间的合作为特征，促进创新治疗的发现。这两个部门的动态特性使它们处于分子建模市场进步的前沿，药物开发保持其强势地位，而药物发现则捕捉新的机会。 ### 按最终用户：制药与生物技术公司（最大）与研究与学术中心（增长最快） 美国分子建模市场在领先的细分市场价值之间看到显著的市场份额分布。制药和生物技术公司占据了最大的份额，利用先进的分子建模技术进行药物发现和开发。他们在专业软件和人才上的投资增强了他们的竞争优势，导致该部门的显著增长。相比之下，研究和学术中心代表了一个快速扩张的细分市场，吸引了越来越多的资金和对分子建模的兴趣，旨在教育和创新研究。 美国分子建模市场内的增长趋势主要受到技术进步和对个性化医学日益重视的影响。制药和生物技术公司越来越多地采用高通量虚拟筛选和预测建模来简化其流程。研究和学术中心作为有影响力的参与者正在崛起，受到资助和资金的推动，这些资金促进了合作并使其能够获得尖端的分子建模工具，从而增强其研究能力和在现实场景中的应用。 制药与生物技术公司（主导）与研究与学术中心（新兴） 制药和生物技术公司是美国分子建模市场的主导力量，其特点是拥有丰富的资源和严格的研发活动。他们利用复杂的软件平台，整合各种分子建模技术，促进新治疗药物的发现和药物配方的优化。与此同时，研究和学术中心作为新兴参与者，通过利用计算工具的进步来获得关注，开展创新研究项目。他们通常与行业同行合作，这不仅增强了他们的信誉，还促进了知识转移和获得最先进技术的机会。制药公司的既定主导地位与学术机构日益增长的影响力之间的相互作用，塑造了一个动态的市场格局，推动了市场的增长和创新。 ## Competitive Benchmarking 分子建模市场目前的特点是动态竞争格局，受到计算技术进步和对药物发现与开发需求增加的推动。Schrodinger（美国）、Accelrys（美国）和OpenEye Scientific Software（美国）等关键参与者处于前沿，利用创新解决方案增强其市场定位。Schrodinger（美国）专注于将人工智能（AI）整合到其分子建模平台中，这似乎显著提高了药物设计中的预测准确性。与此同时，Accelrys（美国）强调与学术机构的合作，以促进研究和开发，从而增强其技术能力并扩大用户基础。总体而言，这些策略促成了一个日益依赖技术创新和合作努力的竞争环境。在商业策略方面，公司越来越多地本地化其运营，以更好地服务于区域市场并优化供应链。市场结构适度分散，多个参与者争夺市场份额，但大型公司的影响仍然显著。这种竞争结构允许提供多样化的产品，满足分子建模领域内从制药到材料科学的各个细分市场。 在十月，Schrodinger（美国）宣布与一家领先的制药公司建立战略合作关系，共同开发基于AI的药物发现平台。这一合作有望增强Schrodinger在预测建模方面的能力，可能导致更快和更高效的药物开发过程。这一合作关系的战略重要性在于其能够结合资源和专业知识，从而加速该领域的创新。 在九月，OpenEye Scientific Software（美国）推出了一种新的基于云的平台，旨在促进研究人员之间的协作分子建模工作。这一举措反映了行业数字化转型的日益增长趋势，使实时数据共享和分析成为可能。这一举措的战略意义在于日益增加的研究协作工具的需求，这可以提高生产力并促进创新。 在八月，Accelrys（美国）通过收购一家专注于分子模拟的小型生物技术公司来扩大其产品供应。这一收购可能会增强Accelrys的产品组合，使其能够为客户提供更全面的解决方案。这一收购的战略重要性在于其可能增强Accelrys的技术能力和市场覆盖，令公司在竞争对手中处于有利地位。 截至十一月，分子建模市场的当前趋势包括明显向数字化、可持续性和AI技术整合的转变。战略联盟日益塑造竞争格局，因为公司认识到合作在推动创新中的价值。展望未来，竞争差异化似乎将从传统的基于价格的竞争转向关注技术进步、创新和供应链可靠性。这一转变表明，优先考虑这些领域的公司可能在快速发展的市场中获得竞争优势。 ## Recent News & Developments 美国分子建模市场最近活跃，BIOVIA和达索系统等公司专注于提升其软件能力，以更好地服务于制药和生物技术行业。在2023年9月，Schrodinger宣布与一家领先的生物技术公司达成重要合作，以通过先进的分子模拟增强药物发现过程。 此外，Sygnature Discovery和Hillhouse Capital被报道正在合作开展一项新项目，旨在利用机器学习进行分子建模，以更好地预测药物相互作用。在并购方面，OpenEye Scientific Software收购了一家小型初创公司的技术资产，以增强其计算能力，该消息在2023年10月公开宣布。 市场已经看到显著增长，最近的估值超过10亿美元，受到Luminex和ChemAxon等公司在科学研究平台上增加研发投资的推动。在过去几年中，个性化医疗的重视和人工智能的进步塑造了市场动态，促使关键参与者在分子建模中寻求创新解决方案。 ## Report Scope | 2024年市场规模 | 9500（美元百万） | | --- | --- | | 2025年市场规模 | 1104.8（美元百万） | | 2035年市场规模 | 5000（美元百万） | | 复合年增长率（CAGR） | 16.3%（2025 - 2035） | | 报告覆盖范围 | 收入预测、竞争格局、增长因素和趋势 | | 基准年 | 2024 | | 市场预测期 | 2025 - 2035 | | 历史数据 | 2019 - 2024 | | 市场预测单位 | 美元百万 | | 关键公司简介 | Schrodinger（美国），Accelrys（美国），Biovia（美国），ChemAxon（匈牙利），Molecular Simulations（美国），OpenEye Scientific Software（美国），Cresset（英国），Simulations Plus（美国），Zinc（美国） | | 覆盖的细分市场 | 产品、应用、最终用户 | | 关键市场机会 | 人工智能的进步增强了分子建模市场的预测能力。 | | 关键市场动态 | 技术进步推动了分子建模中的创新，增强了药物发现和开发过程。 | | 覆盖的国家 | 美国 | ## Frequently Asked Questions **Q: 2024年美国分子建模市场的市场估值是多少？** A: 市场估值在2024年为9500万美元。 **Q: 到2035年，美国分子建模市场的预计市场估值是多少？** A: 2035年的预计市场估值为5亿美元。 **Q: 在2025年至2035年的预测期内，美国分子建模市场的预期年均增长率是多少？** A: 在预测期内，市场的预期年均增长率为16.3%。 **Q: 哪些公司被认为是美国分子建模市场的关键参与者？** A: 关键参与者包括Schrodinger、Accelrys、Biovia、ChemAxon、Molecular Simulations、OpenEye Scientific Software、Cresset、Simulations Plus和Zinc。 **Q: 美国分子建模市场的主要产品细分是什么？** A: 主要产品细分为软件，估值在4000万美元到2亿美元之间，以及服务，估值在5500万美元到3亿美元之间。 **Q: 哪些应用推动了美国分子建模市场的增长？** A: 主要应用包括药物开发，估值在4000万美元到2亿美元之间，以及药物发现，估值在5500万美元到3亿美元之间。 **Q: 美国分子建模的主要终端用户是谁？** A: 主要终端用户包括制药和生物技术公司，估值在6000万美元到3.2亿美元之间，以及研究和学术中心，估值在3500万美元到1.8亿美元之间。 **Q: 2024年的市场估值与2035年的预计估值相比如何？** A: 2024年的市场估值为9500万美元，预计到2035年将增长至5亿美元。 **Q: 哪些趋势正在影响美国分子建模市场的增长？** A: 趋势包括软件能力的进步和对药物发现与开发的投资增加。 **Q: 2025年至2035年预计增长对利益相关者有什么重要性？** A: 预计的增长表明对利益相关者有实质性的机会，市场扩展的潜力由创新和需求驱动。 --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-molecular-modeling-market-19449*